Bayer Aktiengesellschaft Earnings Recaps
Q3 2025
Nov 14, 2025
The company reported a slight increase in sales and a 7% year-over-year gain in core EPS to EUR 4.29, while navigating challenges in Consumer Health and ongoing regulatory effects in Crop Science.
Key takeaways
- Core EPS increased by 7% year-over-year to EUR 4.29, reflecting operational efficiency gains.
- While Crop Science showed resilience with a 9% growth in corn sales, regulatory effects have led to a 2% decline in the Core Crop Protection business.
- Pharmaceuticals segment propelled by strong sales of Nubeqa and Kerendia, up 60% and 80% respectively, despite pressures on Eylea.
- Anticipate challenges in Consumer Health, revising full-year sales growth expectations downward due to a soft market environment.
- FDA approval for Lynkuet and progress in cell and gene therapies indicate ongoing commitment to innovation and future growth prospects.